Intensity Therapeutics Common Stock Market Value
| INTS Stock | 0.38 0.01 2.56% |
| Symbol | Intensity |
Is there potential for Stock market expansion? Will Intensity introduce new products? Factors like these will boost the valuation of Intensity Therapeutics. Market participants price Intensity higher when confident in its future expansion prospects. Understanding fair value requires weighing current performance against future potential. All the valuation information about Intensity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Intensity Therapeutics is measured differently than its book value, which is the value of Intensity that is recorded on the company's balance sheet. Investors also form their own opinion of Intensity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intensity Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Intensity Therapeutics' market value can be influenced by many factors that don't directly affect Intensity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intensity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intensity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Intensity Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Intensity Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Intensity Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Intensity Therapeutics.
| 10/31/2025 |
| 01/29/2026 |
If you would invest 0.00 in Intensity Therapeutics on October 31, 2025 and sell it all today you would earn a total of 0.00 from holding Intensity Therapeutics Common or generate 0.0% return on investment in Intensity Therapeutics over 90 days. Intensity Therapeutics is related to or competes with Iterum Therapeutics, Rallybio Corp, IBio Common, Pluri, Boundless Bio, Plus Therapeutics, and NextCure. More
Intensity Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Intensity Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Intensity Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 51.11 | |||
| Value At Risk | (12.90) | |||
| Potential Upside | 10.87 |
Intensity Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Intensity Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Intensity Therapeutics' standard deviation. In reality, there are many statistical measures that can use Intensity Therapeutics historical prices to predict the future Intensity Therapeutics' volatility.| Risk Adjusted Performance | (0.06) | |||
| Jensen Alpha | (0.94) | |||
| Total Risk Alpha | (1.33) | |||
| Treynor Ratio | (0.26) |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Intensity Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Intensity Therapeutics January 29, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.25) | |||
| Mean Deviation | 5.27 | |||
| Coefficient Of Variation | (983.78) | |||
| Standard Deviation | 7.68 | |||
| Variance | 58.95 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.94) | |||
| Total Risk Alpha | (1.33) | |||
| Treynor Ratio | (0.26) | |||
| Maximum Drawdown | 51.11 | |||
| Value At Risk | (12.90) | |||
| Potential Upside | 10.87 | |||
| Skewness | 0.8758 | |||
| Kurtosis | 4.2 |
Intensity Therapeutics Backtested Returns
Intensity Therapeutics holds Efficiency (Sharpe) Ratio of -0.1, which attests that the entity had a -0.1 % return per unit of risk over the last 3 months. Intensity Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please check out Intensity Therapeutics' Risk Adjusted Performance of (0.06), standard deviation of 7.68, and Market Risk Adjusted Performance of (0.25) to validate the risk estimate we provide. The company retains a Market Volatility (i.e., Beta) of 3.01, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Intensity Therapeutics will likely underperform. At this point, Intensity Therapeutics has a negative expected return of -0.78%. Please make sure to check out Intensity Therapeutics' maximum drawdown, daily balance of power, as well as the relationship between the Daily Balance Of Power and relative strength index , to decide if Intensity Therapeutics performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.03 |
Virtually no predictability
Intensity Therapeutics Common has virtually no predictability. Overlapping area represents the amount of predictability between Intensity Therapeutics time series from 31st of October 2025 to 15th of December 2025 and 15th of December 2025 to 29th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Intensity Therapeutics price movement. The serial correlation of 0.03 indicates that only 3.0% of current Intensity Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.03 | |
| Spearman Rank Test | 0.07 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Intensity Stock Analysis
When running Intensity Therapeutics' price analysis, check to measure Intensity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intensity Therapeutics is operating at the current time. Most of Intensity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intensity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intensity Therapeutics' price. Additionally, you may evaluate how the addition of Intensity Therapeutics to your portfolios can decrease your overall portfolio volatility.